Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIP-seq of STAT5B in human ALCL cell lines and CDK6 in a murine ALCL cell line

ABSTRACT: To investigate direct genomic targets of CDK6 and STAT5B in Anaplastic Large Cell Lymphoma (ALCL), ChIP-sequencing (ChIP-seq) was performed in both human and murine ALCL cell lines. We performed ChIP targeting STAT5B in five human ALCL cell lines (SU-DHL-1, DEL, SUP-M2, Karpas-299, SR-786) and ChIP targeting CDK6 in one murine ALCL cell line derived from a NPM-ALK(Tg/+) mouse.

INSTRUMENT(S): Illumina NovaSeq X

ORGANISM(S): Homo sapiens

SUBMITTER: Thorsten Klampfl

PROVIDER: E-MTAB-15481 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq of human and murine ALCL cell lines to compare interspecies similarity and genetic dependencies on CDK6 or STAT5B

Project description:To explore transcriptional similarities between human and murine Anaplastic Large Cell Lymphoma (ALCL) cell lines, RNA sequencing was performed across both species. The human cell lines included SU-DHL-1, DEL, SUP-M2, Karpas-299, SR-786, Mac1 and Mac2a. Additionally, murine cell lines derived from tumors with distinct genetic backgrounds (NPM-ALK(Tg/+), NPM-ALK(Tg/+)Cdk6-/- and NPM-ALK(Tg/+)Stat5b-/-) were analyzed to identify gene expression differences associated with tumor development in the absence of CDK6 or STAT5B.

2026-07-24 | E-MTAB-15486 | biostudies-arrayexpress

ChIP-seq of STAT5B in human ALCL cell lines and CDK6 in a murine ALCL cell line

Project description:ChIP-seq of STAT5B in human ALCL cell lines and CDK6 in a murine ALCL cell line

| PRJEB95978 | ENA

Gene expression changes associated with kinase-inactivated Cdk6 or a complete Cdk6 KO in mouse HSC/MPP1 cells after two rounds of transplantation

Project description:A kinase-inactivated variant of Cdk6 (Cdk6_K43M) was associated with prolonged repopulation potential of mouse lineage-negative, Sca1-positive, cKit-positive, CD150-positive, CD48-negative (HSC/MPP1) cells. In order to understand differences between Cdk6_K43M HSC/MPP1 cells, and HSC/MPP1 cells carrying wild-type Cdk6 (Cdk6_WT) or a complete Cdk6 knock-out (Cdk6_KO) in the context of repopulation the following experiment was performed. Pools of freshly isolated CD45.2-positive HSC/MPP1 cells from mice carrying Cdk6_WT, Cdk6_K43M or Cdk6_KO (all homozygous) were serially transplanted into three CD45.1-positive recipients, per genotype. After two rounds of transplantation, CD45.2-positive HSC/MPP1 cells were isolated using flow cytometry based cell sorting and subjected to library prep for RNA sequencing.

2024-05-22 | E-MTAB-13145 | biostudies-arrayexpress

RNA-Seq of FACS-sorted ex vivo NK cells from control (Cre neg, GFPNK/NK), STAT5BNK/NK, N642HNK/NK and diseased N642HNK/NK mice

Project description:Somatic STAT5B gain-of-function mutations have been frequently found in patients with T- and NK-cell neoplasms. STAT5BN642H represents the most frequently occuring STAT5B mutation. To investigate the molecular mechanism of STAT5BN642H-driven NK-cell leukemia, we performed RNA-Seq of liver derived FACS-sorted diseased N642HNK/NK and aged non-diseased control (Cre neg, GFPNK/NK), STAT5BNK/NK, N642HNK/NK NK cells.

2024-05-01 | E-MTAB-13797 | biostudies-arrayexpress

Identification of sites bound by c-Jun and JunB transcription factors in the Karpas 299 ALK+ ALCL cell line

Project description:In order to identify sites bound by c-Jun/JunB in ALK+ ALCL, we performed ChIP-Seq on the Karpas 299 ALK+ ALCL cell line.

2020-09-01 | GSE151413 | GEO

JAK dependent survival of ALK- ALCL

Project description:Activating JAK and STAT mutations were discovered in many T-cell malignancies including ALK- anaplastic large cell lymphomas (ALCL). However, such mutations often occur in a minority of patients. To investigate the clinical application of targeting Janus Kinase (JAK) for ALK- ALCL, we treated ALK- cell lines of different histologic origins with JAK inhibitors. Interestingly, most exogenous cytokine independent cell lines responded to JAK inhibition regardless of JAK mutation status. JAK inhibitor sensitivity correlated with STAT3 phosphorylation status of tumor cells. Employing retroviral shRNA knockdown, we demonstrated that these JAK inhibitor sensitive cells were dependent on both JAK1 and STAT3 for survival. JAK1 and STAT3 gain-of-function mutations were found in some but not all JAK inhibitor sensitive cells. Moreover, the mutations alone could not explain the JAK1/STAT3 dependency as wild-type JAK1 or STAT3 was sufficient to promote cell survival in the cells that had either JAK1or STAT3 mutations. To investigate whether other mechanisms were involved, we knocked down upstream receptors GP130 or IL-2Rγ. Knockdown of GP130 or IL-2Rγ induced cell death in select JAK inhibitor sensitive cells. High levels of cytokine expression including IL-6 were demonstrated in cell lines as well as in primary ALK- ALCL tumors. Finally, ruxolitinib, a JAK1/2 inhibitor, was effective in vivo in a xenograft ALK- ALCL model. Our data suggest cytokine receptor signaling was required for tumor cell survival in diverse forms of ALK- ALCL even in the presence of JAK1/STAT3 mutations. Therefore, JAK-inhibitor therapy might benefit patients with ALK- ALCL that are pSTAT3+.

2017-08-22 | GSE96048 | GEO

RNA-seq of human and murine ALCL cell lines to compare interspecies similarity and genetic dependencies on CDK6 or STAT5B

Project description:RNA-seq of human and murine ALCL cell lines to compare interspecies similarity and genetic dependencies on CDK6 or STAT5B

| PRJEB95989 | ENA

Single cell RNA-seq to investigate transcriptional profiles of thymic double negative T cells in WT, NPM-ALK(Tg/+) and NPM-ALK(Tg/+)Cdk6-/-Stat5b-/- mice

Project description:To examine transcriptional differences in thymic double negative (DN) T cells between wildtype (WT), NPM-ALK(Tg/+) and NPM-ALK(Tg/+)Cdk6-/-Stat5b-/- mice, single-cell RNA sequencing (scRNA-seq) was performed on fluorescence-activated cell sorted (FACS) DN T cells. The aim was to understand how genetic alterations in the NPM-ALK(Tg/+) and NPM-ALK(Tg/+)Cdk6-/-Stat5b-/- backgrounds influence early T cell development and oncogenic transformation at the transcriptional level.

2026-07-24 | E-MTAB-15478 | biostudies-arrayexpress

Effect of ALK kinase inhibitor, ceritinib, on the gene expression profile of SUDHL-1 cell line

Project description:Tyrosine kinase receptor anaplastic lymphoma kinase (ALK) is physiologically expressed during embryogenesis. However, chromosomal rearrangements, especially translocations, cause expression of pathogenic ALK fusion proteins that drive tumor formation and maintenance. For instance, the translocation between chromosomes 2 and 5 (t(2;5)) fuses the nucleophosmin 1 (NPM1) gene with ALK, leading to anaplastic large cell lymphoma (ALCL). The constitutive active NPM1::ALK tyrosine kinase drives tumor transformation and tumor cells inevitably depend on ALK kinase activity for survival. For this reason, ALK kinase inhibitors showed great success in treating ALK-positive ALCL. Here, we explored gene expression changes induced by ceritinib, second generation ALK inhibitor, on a representative cell line, SUDHL-1.

2026-01-01 | E-MTAB-15866 | biostudies-arrayexpress

ChIP sequencing experiment of HA-tagged WT CDK6 or of a C-terminally truncated variant of CDK6 (CDK6 delta-C) in BCR-ABL1 expressing cell lines

Project description:The cell cycle kinase CDK6 interacts with a variety of proteins including cyclins and members of the INK4 and Cip/Kip families. These interactions are thought to involve primarily the N-lobe of the protein. Less is known about the role of the C-lobe for the function of CDK6. In this experiment we assessed the function of the C-lobe in CDK6's interaction with transcriptional complexes. We generated cell lines by retroviral over-expression of BCR-ABL1 in bone marrow cells from CDK6 knock-out mice. We then introduced HA-tagged variants of CDK6 - either wildtype CDK6 (CDK6_WT) or a C-terminally truncated variant of CDK6 lacking the last 32 amino acids of the protein (CDK6_delta-C). ChIP was performed with an antibody against the HA tag. CDK6 KO cell lines were used as controls.

2024-06-30 | E-MTAB-13798 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data